Pharma BD Deal Intelligence
A $150M bet on antiviral discovery that produced zero approved products and was put up for sale within three years
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
John Patterson, Executive Director, Development: 'Arrow Therapeutics is an excellent opportunity to acquire a world-class anti-viral capability to add to our…
AstraZeneca pays $150M for Arrow Therapeutics, adding antiviral programs against hepatitis C and respiratory syncytial virus to enhance its anti-infective…
Post-deal coverage notes Arrow continued to operate as an autonomous unit at its London site as a self-contained antiviral discovery hub for AstraZeneca, an…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
AstraZeneca acquired Arrow Therapeutics for $150 million in cash to add Phase II antiviral programs (RSV604 and HCV NS5A compounds) and a London-based discovery team to its anti-infectives pipeline. The acquisition closed on 2 March 2007.
A $150M bet on antiviral discovery that produced zero approved products and was put up for sale within three years
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Arrow Therapeutics Ltd. (this deal) | 2007 | $150M | 13 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2007 deals · AstraZeneca PLC deals